Article
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
JAMA - 21 May 2014
Kris Mark G, Johnson Bruce E, Berry Lynne D, Kwiatkowski David J, Iafrate A John, Wistuba Ignacio I, Varella-Garcia Marileila, Franklin Wilbur A, Aronson Samuel L, Su Pei-Fang, Shyr Yu, Camidge D Ross, Sequist Lecia V, Glisson Bonnie S, Khuri Fadlo R, Garon Edward B, Pao William, Rudin Charles, Schiller Joan, Haura Eric B, Socinski Mark, Shirai Keisuke, Chen Heidi, Giaccone Giuseppe, Ladanyi Marc, Kugler Kelly, Minna John D, Bunn Paul A
Abstract excerpt
IMPORTANCE: Targeting oncogenic drivers (genomic alterations critical to cancer development and maintenance) has transformed the care of patients with lung adenocarcinomas. The Lung Cancer Mutation Consortium was formed to perform multiplexed assays testing adenocarcinomas of the lung for drivers in 10 genes to enable clinicians to select targeted treatments and enroll patients into clinical trials. OBJECTIVES:...
Topics
- Adenocarcinoma
- Adenocarcinoma of Lung
- Aged
- Female
- Genotype
- Humans
- Lung Neoplasms
- Male
- Middle Aged